Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
Дата публикации: 16-09-2026 07:09:00

Evidence for efficacy is based on the results from the ARROS-1 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer023.0722-07-2026
2FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
3FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally Advanced or metastatic breast cancer014.9109-09-2026
4FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma09.1822-07-2026
5FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
6Daraxonrasib shows antitumour activity in patients with previously treated metastatic RAS-mutated NSCLC015.8810-09-2026
7Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC01527-07-2026
8FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
9Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector 016.2510-07-2026
10В России зарегистрировали препарат от агрессивной формы рака01019-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 18.14. Источник: www.esmo.org.